Please ensure Javascript is enabled for purposes of website accessibility

Heartburn Relieved ... for Now

By Brian Orelli, PhD – Updated Apr 6, 2017 at 2:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AstraZeneca settles its patent dispute with Teva.

Investors might need a little less of AstraZeneca's (NYSE:AZN) heartburn reliever, Nexium, after the drugmaker settled a patent dispute with generic-drug maker Teva Pharmaceuticals (NASDAQ:TEVA) yesterday.

The deal resembles the one AstraZeneca struck with Ranbaxy in 2008, giving Ranbaxy and Teva the right to launch generic versions of Nexium in the U.S. in May 2014, when the first patent on the drug expires. In exchange for not enforcing other patents, AstraZeneca doesn't have to worry about losing a patent challenge in court.

Dr. Reddy's Laboratories (NYSE:RDY), Novartis (NYSE:NVS), and Lupin have also challenged Nexium's patents, but considering the conciliatory moves by Ranbaxy and Teva, it seems likely that the other drugmakers will follow suit.

Nexium is extremely important to AstraZeneca and, to a lesser extent, Merck (NYSE:MRK), which co-markets the drug. The purple pill brought in nearly $3.7 billion -- 15% of AstraZeneca's revenue -- in the first nine months of the year. Sales in the U.S. have been slipping a little because of price cuts, as the drugmaker deals with competition, including generic versions of its own Prilosec, which is available as a over-the-counter version marketed by Procter & Gamble (NYSE:PG).

Unfortunately, investors may have to break out the Nexium again shortly. AstraZeneca has a court case over its patents on cholesterol drug Crestor next month. Crestor is another biggie, coming in third on AstraZeneca's list of top drugs. Crestor's sales are only slightly behind those of Nexium and Seroquel, and it's on pace to catch them shortly, with year-over-year growth of 24% so far this year.

Such is the life of drug company investors. Between FDA decisions and patent disputes, it's difficult to keep your stomach from churning.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Novartis is a Motley Fool Global Gains selection. Procter & Gamble is a Motley Fool Income Investor selection in which the Fool owns shares. The Fool's disclosure policy should make you feel a little better inside.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.78 (-0.83%) $0.73
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.58 (-3.07%) $-1.73
The Procter & Gamble Company Stock Quote
The Procter & Gamble Company
PG
$135.58 (-0.46%) $0.63
Novartis AG Stock Quote
Novartis AG
NVS
$76.01 (-1.47%) $-1.13
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.90 (-1.98%) $0.16
Dr. Reddy's Laboratories Limited Stock Quote
Dr. Reddy's Laboratories Limited
RDY
$50.65 (-1.31%) $0.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.